Skip to main content

Clinical trial 1367.1

An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit

Cancers
Organ Multiple
Trial status Trial closed
Investigator
Trial type
Interventional with experimental drug
Phase Trial phase 1
Academic trial Non
Sponsor Boehringer Ingelheim
EudraCT Identifier 2015-001111-12
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02516553
Inclusion criteria any line RECIST 1.1
Last update